

BACKGROUND

It is important for cancer centers to right-size trial portfolios based on their community. To ensure the UFHCC portfolio contains the appropriate number of trials, and provide appropriate resources dedicated to each disease site group (DSG), the “parking lot” framework was devised and implemented in 2022.

GOALS

The parking lot aims to (a) support treatment trial accruals by tailoring the trial portfolio to the unique makeup of the outpatient population, (b) right-size DSG portfolios relative to patient populations reflected in Data Table 3 and (c) encourage DSGs to be discerning about trials brought forward, so that Clinical Research Office (CRO) resources can focus on trials most likely to succeed, while allowing for some flexibility to consider some smaller, targeted studies.

CONTACT

ERIN MONARI, PhD, CCRC
Director of Clinical Research

University of Florida Health Cancer Center
2033 Mowry Road
Gainesville FL 32610

352-273-8128
clh1230@ufl.edu




METHODS

Each DSG is assigned a “parking lot,” in which they are allowed to place studies. The number of spaces in each parking lot is driven by the DSG’s number of reportable cases, while focusing on CRO staff effort; trials supported by non-CRO staff are not subject to parking lot rules.

Parking Lot Rules:

- All parking lot spaces are reserved for treatment studies.
- Trials are dedicated a single space; however, complex trials may use two spaces (e.g. CAR-T, Phase 1, basket-type studies, etc.).
- Studies exit their space once permanently closed to accrual.
- Studies can enter development prior to space availability; however, cannot open to accrual without a dedicated space.
- Additional spaces are awarded by meeting or exceeding accrual targets or extramural dollars to support additional effort



OUTCOMES

Benefits

- Staff assignments partly based on size of parking lot
- Assist in identifying new staff assignments
- Helps define clear expectations based on
 - Patient population
 - Target enrollment
- Allows DSGs flexibility in opening trials with varying degrees of anticipated enrollment
- Help assess how well DSGs are covering effort costs
- Assists leadership review of DSG performance
 - Enrollment to treatment trial goals
 - Potential for immediate and future growth

In 2023, treatment trial accruals increased 21% from 2022, indicating DSG mindfulness since parking lot development. DSGs have been able to open smaller trials of interest as well, supported by larger trials within their parking lot.

FUTURE DIRECTIONS

We hope to further refine when studies would require multiple parking spaces. Workload and study complexity evaluation tools are being explored for this assessment.

Another development consideration will be how to treat IITs in development, and timing for space allocation prior to study activation.